BIOA (BioAge Labs, Inc.) Stock Market Reviews

crown

search

Read and share opinions on BIOA (BioAge Labs, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

BIOA

BioAge Labs, Inc.

clarify Drug Manufacturers - Specialty & Generic

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

BioAge Labs to Present at Jefferies Global Healthcare Conference in London
Nov 7, 2025
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
Nov 6, 2025
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
Sep 15, 2025
BioAge Labs to Present at Upcoming Investor Conferences
Aug 20, 2025
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Aug 6, 2025
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery
Jul 29, 2025
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Jun 21, 2025
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
Jun 17, 2025
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
Jun 3, 2025
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
May 30, 2025
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
May 29, 2025
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
May 6, 2025
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest
May 6, 2025
BioAge Labs, Inc. (BIOA): A Bull Case Theory
Apr 21, 2025

Reviews